$DRMA
Dermata Therapeutics Inc

2024 Q2 Form 10-Q Financial Statement

#000165495424006398 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $874.6K $1.603M
YoY Change -2.11% 47.72%
% of Gross Profit
Research & Development $2.009M $1.601M
YoY Change 139.48% 34.22%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.884M $3.204M
YoY Change 66.46% 40.65%
Operating Profit -$2.884M -$3.204M
YoY Change 66.46% 40.65%
Interest Expense $54.64K $69.30K
YoY Change 75.97% 84.6%
% of Operating Profit
Other Income/Expense, Net $1.400M
YoY Change
Pretax Income -$2.829M -$3.134M
YoY Change 66.29% 39.91%
Income Tax
% Of Pretax Income
Net Earnings -$2.829M -$3.134M
YoY Change 66.28% 39.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.18 -$0.47
COMMON SHARES
Basic Shares Outstanding 6.661M shares 6.661M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.947M $4.734M
YoY Change -41.37% -46.0%
Cash & Equivalents $4.947M $4.734M
Short-Term Investments
Other Short-Term Assets $289.5K $446.1K
YoY Change 5.81% -14.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.237M $5.180M
YoY Change -39.9% -44.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.00 -$4.00
YoY Change 100.0% -20.0%
TOTAL ASSETS
Total Short-Term Assets $5.237M $5.180M
Total Long-Term Assets $2.00 -$4.00
Total Assets $5.237M $5.180M
YoY Change -39.9% -44.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.327M $822.5K
YoY Change 203.16% 66.89%
Accrued Expenses $591.3K $549.2K
YoY Change 141.25% -23.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.918M $1.372M
YoY Change 180.94% 13.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.918M $1.372M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.918M $1.372M
YoY Change 180.94% 13.65%
SHAREHOLDERS EQUITY
Retained Earnings -$59.35M -$56.52M
YoY Change 19.82% 18.16%
Common Stock $69.00 $666.00
YoY Change -78.37% 178.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.318M $3.808M
YoY Change
Total Liabilities & Shareholders Equity $5.237M $5.180M
YoY Change -39.9% -44.27%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$2.829M -$3.134M
YoY Change 66.28% 39.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.126M -$2.704M
YoY Change 15.52% 63.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.339M $0.00
YoY Change 54.71% -100.0%
NET CHANGE
Cash From Operating Activities -2.126M -$2.704M
Cash From Investing Activities
Cash From Financing Activities 2.339M $0.00
Net Change In Cash 213.5K -$2.704M
YoY Change -165.03% -207.09%
FREE CASH FLOW
Cash From Operating Activities -$2.126M -$2.704M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1192633 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1371766 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1623616 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
666 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
393 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60329464 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59742503 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56522140 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53387878 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3807990 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6355018 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5179756 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7978634 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
446075 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
540499 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
822546 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
866028 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1602819 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3203560 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3203560 usd
CY2023Q4 us-gaap Assets
Assets
7978634 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1085049 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7438135 usd
CY2024Q1 us-gaap Assets
Assets
5179756 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
549220 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
757588 usd
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001853816
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6660840 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3930840 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40739
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
DERMATA THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3218736
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3525 Del Mar Heights Rd
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
#322
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
800-2543
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6660840 shares
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4733681 usd
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6660840 shares
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1600741 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2277682 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2277682 usd
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
69298 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
37540 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3134262 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240142 usd
CY2024Q1 drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.47
CY2023Q1 drma Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-2.27
CY2024Q1 drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
6660840 shares
CY2023Q1 drma Weighted Average Basic And Diluted Common Units Shares
WeightedAverageBasicAndDilutedCommonUnitsShares
985848 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6355018 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
587234 usd
CY2024Q1 drma Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3134262 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3807990 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6021854 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131260 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4174985 usd
CY2024Q1 drma Issuance Of Abeyance Shares Amount
IssuanceOfAbeyanceSharesAmount
0 usd
CY2023Q1 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
153 usd
CY2023Q1 drma Settlement Of Fractional Shares Paid In Cash Amount
SettlementOfFractionalSharesPaidInCashAmount
-40 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8088070 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
3134262 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
2240142 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
587234 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
131260 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-94424 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-174848 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-43482 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3831 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-208368 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
288232 usd
CY2024Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
429808 usd
CY2023Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
590509 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2704454 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1649633 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4174985 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
153 usd
CY2024Q1 drma Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
0 usd
CY2023Q1 drma Payment For Fractional Shares In Reverse Stock Split
PaymentForFractionalSharesInReverseStockSplit
40 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4175098 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2704454 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2525465 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7438135 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6241294 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4733681 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8766759 usd
CY2024Q1 drma Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
-273 usd
CY2023Q1 drma Noncash Transaction Issuance Of Abeyance Shares
NoncashTransactionIssuanceOfAbeyanceShares
0 usd
CY2024Q1 drma Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
0 usd
CY2023Q1 drma Noncash Transaction Incremental Fair Value Of Warrant Modification
NoncashTransactionIncrementalFairValueOfWarrantModification
144765 usd
CY2021Q3 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
24106 shares
CY2021Q3 drma Class Of Warrant Or Right Exercise Price Of Warrants Or Right
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight
112.00
CY2024Q1 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
4700000 usd
CY2024Q1 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
56500000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
2700000 usd
CY2023 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
6400000 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8768940 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3888691 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.82
CY2023Q4 drma Offering Expenses
OfferingExpenses
300000 usd
CY2024Q1 drma Description Of Abeyance Shares
DescriptionOfAbeyanceShares
the Holder left 2,730,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request, which were then delivered to the Holder on January 8, 2024
CY2023Q2 drma Proceeds Cash From Pipe
ProceedsCashFromPipe
1500000 usd
CY2023Q2 drma Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
300000 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8358697 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8358697 shares
CY2023Q4 drma Warrants To Purchase Up To Shares Of Common Stock
WarrantsToPurchaseUpToSharesOfCommonStock
3472095 shares
CY2023Q4 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
0.6511
CY2023Q4 drma Class Of Warrant Or Right Exercise Price Reduced Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceReducedOfWarrantsOrRights
0.6511
CY2023Q4 drma Received Net Cash Proceeds
ReceivedNetCashProceeds
2000000.0 usd
CY2024Q1 drma Warrant Reduced Description
WarrantReducedDescription
from $21.20 to $2.82 per share upon closing of the March 2023 Offering
CY2024Q1 drma Description Of Stock Option Cancellation
DescriptionOfStockOptionCancellation
in accordance with an option cancellation agreement. Accordingly, 101,831 of the 102,074 stock options outstanding as of December 31, 2023, were cancelled in February 2024
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
568372 usd
CY2024Q1 drma Common Stock Par Or Stated Values Per Share
CommonStockParOrStatedValuesPerShare
0.4108
CY2024Q1 us-gaap Contractually Specified Servicing Fees Amount
ContractuallySpecifiedServicingFeesAmount
6900000 usd
CY2024Q1 us-gaap Other Expenses
OtherExpenses
1400000 usd

Files In Submission

Name View Source Status
0001654954-24-006398-index-headers.html Edgar Link pending
0001654954-24-006398-index.html Edgar Link pending
0001654954-24-006398.txt Edgar Link pending
0001654954-24-006398-xbrl.zip Edgar Link pending
drma-20240331.xsd Edgar Link pending
drma_10q.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
drma-20240331_cal.xml Edgar Link unprocessable
drma-20240331_def.xml Edgar Link unprocessable
drma-20240331_lab.xml Edgar Link unprocessable
drma-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drma_10q_htm.xml Edgar Link completed